


Israpafant

| | |
|--------------------|---|
| Cat. No.: | HY-106837 |
| CAS No.: | 117279-73-9 |
| Molecular Formula: | C ₂₈ H ₂₉ ClN ₄ S |
| Molecular Weight: | 489.07 |
| Target: | Platelet-activating Factor Receptor (PAFR) |
| Pathway: | GPCR/G Protein |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC ₅₀ s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca ²⁺ influx and intracellular Ca ²⁺ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice ^{[1][2]} . |
| IC ₅₀ & Target | IC ₅₀ : 0.84 nM (PAF-induced human platelet aggregation), 3.84 nM (PAF-induced rabbit platelet aggregation) ^[1] |

REFERENCES

- [1]. Takehara S, et al. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Prostaglandins. 1990 Dec;40(6):571-83.
- [2]. Jan C R, Chao Y Y. Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca²⁺ levels and growth of human prostate cancer cells. Cellular signalling, 2004, 16(8): 959-965.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA